Found 2131 clinical trials
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval Study (REDUCE PAS)
The GORE GSO 18-01 study is a Post Approval Study assessing the safety and effectiveness of the GORE Septal Occluder device as observed in the REDUCE pivotal IDE study, evaluating the quality of operator education and training and transferability of trial experience to a post-market setting.
- 0 views
- 18 Oct, 2021
- 1 location
A Washington University research study seeks participants with history of brain hemorrhage.
The goal of the research study is to generate a biospecimen repository to analyze genes related to subarachnoid hemorrhage outcomes. There will be 1 to 2 study visits. Participation includes blood draw or saliva sample, Rankin scale (measures degree of disability), and telephone interview (IRB # 201812118).
- 27 views
- 02 Dec, 2020
- 1 location
Low Testosterone (Hypogonadism)
Consider joining the TRAVERSE research study for men age 45 to 80 who have symptoms of low testosterone (hypogonadism) and have a history or risk of heart disease or stroke.
- 156 views
- 23 Nov, 2020
- 1 location
Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)
Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus
- 76 views
- 25 Mar, 2021
- 1 location
A Clinical Trial for individuals suffering from Hyperlipidemia (high cholesterol) and are at risk of cardiovascular events (ie: heart attack, stroke, angina.
A Clinical Trial for individuals suffering from Hyperlipidemia (high cholesterol) and are at risk of cardiovascular events (ie: heart attack, stroke, angina.
- 680 views
- 23 Nov, 2020
- 1 location
A multinational, randomized, double-blind, placebo controlled trial to evaluate the effect of Ticagrelor 90mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus.
A multinational, randomized, double-blind, placebo controlled trial to evaluate the effect of Ticagrelor 90mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in
- 70 views
- 23 Nov, 2020
- 1 location
EX9924-4473: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)
Oral Semaglutide
- 102 views
- 23 Nov, 2020
- 1 location
DECLARE -Dapagliflozin Effect on CardiovascuLAR Events - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes
Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes
- 164 views
- 25 Mar, 2021
- 1 location
GUIDE-IT - GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) -The goal of this US prospective outpatient AF registry is to identify real world treatment patterns in patients with AF(atrial fibrillation), outside of randomized controlled trials. Specifically, the registry will attempt to define current treatment patterns and their relationship with outcomes, including stroke, all-cause mortality, and quality-of-life.
, including stroke, all-cause mortality, and quality-of-life.
- 128 views
- 25 Mar, 2021
- 2 locations
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II - ORBIT AF II - Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is designed to evaluate the utilization of target-specific antithrombotic agents, such as factor Xa (FXa) inhibitors and direct thrombin inhibitors, and associated outcomes.
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II - ORBIT AF II - Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is designed to evaluate the utilization of target-specific antithrombotic agents, such as factor Xa (FXa) inhibitors and direct thrombin inhibitors, …
- 89 views
- 08 Nov, 2020
- 1 location